Baxter International stock gains after strong Q2 figures

Baxter International stock is trading higher after a solid second quarter, with growing revenue and improving guidance while the Tradegate listing provides a DACH market angle for investors.

Baxter International stock (ISIN US0673431090) is trading around USD 25.70 as of September 3, 2026, after a strong second quarter that saw revenue rise to USD 2.96 billion, up 5.3% year on year according to a recent healthcare sector teardown.

Q2 2026 numbers underpin the move

According to an analysis of diversified medical devices and supplies stocks, Baxter International reported second quarter 2026 revenue of USD 2.96 billion, representing a 5.3% increase compared with the same period a year earlier.

The same sector review notes that Baxter International beat analysts' expectations on both quarterly earnings per share and full year 2026 earnings guidance, with revenue coming in 6% above consensus and the stock up about 3.2% since the Q2 report, trading near USD 25.57 as of late August 2026.

DACH trading link via Tradegate listing

For investors in the DACH region, Baxter International is available on the German Tradegate Exchange, where the stock recently traded at EUR 22.01 as of September 3, 2026 according to real-time Tradegate market data, showing a 5 day change of minus 0.77% and a performance of plus 36.14% since January 1, 2026.

This year to date performance on Tradegate highlights how Baxter International stock has recovered strongly in 2026, even as day to day moves remain moderate, with the latest closing price snapshot from a US stock portal showing USD 25.65, up 0.66% as of the close on September 2, 2026.

Essential therapies support the business

Baxter International, headquartered in the United States, provides essential healthcare products such as dialysis therapies, intravenous solutions, infusion systems, surgical products and patient monitoring technologies to hospitals and clinics in more than 100 countries, as described in the same diversified healthcare sector overview.

The mix of recurring therapies and hospital supplies typically supports steady cash flows, and the Q2 2026 revenue growth of 5.3% year on year to USD 2.96 billion illustrates how demand for these products has expanded compared with the prior year second quarter, creating room for Baxter International to improve its full year 2026 earnings guidance.

Stock valuation and closing price

Based on recent closing price data from a US stock portal that shows Baxter International at about USD 25.65 as of September 2, 2026, the stock trades near the USD 25.57 level cited in the healthcare sector teardown, indicating that the post results gain of roughly 3.2% has largely been maintained in early September 2026.

For investors, the combination of mid single digit revenue growth in Q2 2026, an earnings beat versus consensus and a year to date performance of more than 36% on German Tradegate suggests that Baxter International stock now reflects improved expectations for the medical technology group while still trading in the mid USD 20s range.

Baxter International at a glance

• Company: Baxter International Inc.
• ISIN: US0673431090
• Ticker: BAX
• Trading venue: NYSE and Tradegate (secondary listing)
• Price (as of September 2, 2026): 25.65 USD
• Market capitalization: 13,000,000,000 USD (as of September 2, 2026, approximate based on recent price and public share count)
• Sector / Industry: Healthcare equipment and supplies
• Index membership: S&P 500